Rupal Patel

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Alexander Drilon, Salvatore Siena, Sai‐Hong Ignatius Ou et al. · Cancer Discovery · 2017 · 817 citations · Full text

Medicine, Oncology, Pharmacology +16

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

Alexander Drilon, Siqing Fu, Manish R. Patel et al. · Cancer Discovery · 2018 · 113 citations · Full text

Medicine, Oncology, Pharmacology +16

Functional and Anatomic Esophagogastic Junction Outflow Obstruction: Manometry, Timed Barium Esophagram Findings, and Treatment Outcomes

Steven Clayton, Rupal Patel, Joel E. Richter · Clinical Gastroenterology and Hepatology · 2016 · 105 citations

Medicine, Clinical Sciences, Surgery +12

Clinical Correlations of α2,6-Sialyltransferase Expression in Colorectal Cancer Patients

Mario Lise, Claudio Belluco, S Perera et al. · Hybridoma · 2000 · 71 citations

Medicine, Oncology, Pathology +13

Antitumor Activity of RXDX-105 in Multiple Cancer Types with <i>RET</i> Rearrangements or Mutations

Gang G. Li, Romel Somwar, James D. Joseph et al. · Clinical Cancer Research · 2016 · 66 citations

Medicine, Oncology, Pharmacology +16